Somatrem: Physiology and What Research Reports

What somatrem is

Somatrem is a recombinant form of human growth hormone that carries one extra amino acid — an N-terminal methionine — in front of the 191-residue human sequence. It was among the first recombinant DNA-derived growth hormone preparations to reach clinical study, and it appears in the older literature under the trade name Protropin, described by researchers as "methionyl human growth hormone" in work on its development and immunogenicity testing (PMID 12434920). Later products used the authentic 191-amino-acid sequence and are named somatropin; analytical reviews of somatropin and its variants have described the structural differences between these related molecules and the laboratory methods used to distinguish them (PMID 15659284).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis, or treatment. Nothing here describes a protocol, and no dosing guidance is offered.

Where growth hormone comes from and what it does

Endogenous growth hormone is a single-chain polypeptide secreted by somatotroph cells of the anterior pituitary gland in pulses, most prominently during slow-wave sleep. Its release is shaped by hypothalamic growth hormone-releasing hormone, by somatostatin acting as a brake, and by feedback from insulin-like growth factor 1. Once in circulation, growth hormone binds a dimerising cell-surface receptor and signals through the JAK2–STAT5 pathway, prompting hepatic and local production of IGF-1.

Downstream, that signalling affects the growth plate (chondrocyte proliferation and linear bone growth in children), protein handling, lipolysis in adipose tissue, and glucose and insulin dynamics. Because somatrem and somatropin are engineered versions of the same hormone, the physiology studied in the clinical literature is the physiology of the growth hormone axis itself, with the added question of whether a non-native N-terminal methionine changes how the immune system sees the molecule.

How somatrem has been measured and studied

Two broad strands of method appear in the verified literature. The first is analytical chemistry: structural characterisation and assay methods for somatropin and its variants have been reviewed in the context of quality control for recombinant hormone preparations (PMID 15659284). The second is clinical and preclinical outcome measurement — height velocity and growth over months to years in paediatric trials, and animal immunogenicity modelling used during product development to anticipate antibody responses (PMID 12434920).

One methodological paper is worth noting on its own: researchers examined knemometry — short-interval lower-leg length measurement — as a way of predicting later response to somatrem in girls with Turner syndrome (PMID 3481183). That reflects a broader research problem of the era: how to tell early whether a growth hormone recipient was responding.

What the clinical literature reports

Children with growth hormone deficiency

Early clinical experience with somatrem in growth hormone deficiency was collected and reported in the mid-1980s, when recombinant material was replacing pituitary-derived hormone (PMID 3296638). A United Kingdom multicentre clinical trial of somatrem was published in 1987 and reported the group's trial findings in treated children (PMID 3310915), following an earlier preliminary UK report of clinical experience with the same preparation (PMID 3296636). A parallel report described clinical experience with somatrem in Japan (PMID 3296635). Taken together, these papers form the first generation of recombinant growth hormone experience rather than a modern evidence base.

Turner syndrome

Turner syndrome, in which short stature occurs without classic growth hormone deficiency, was a major research question for somatrem. One report described treatment of Turner syndrome with recombinant human growth hormone (somatrem) (PMID 3057808), and a separate paper reported results from the first two years of a clinical trial with recombinant DNA-derived human growth hormone in Turner syndrome (PMID 3300157). The knemometry work above sat alongside these trials as an attempt to identify responders early (PMID 3481183).

Adults with growth hormone deficiency

Adult growth hormone deficiency was a newer idea in the 1980s. Researchers reported on substitution therapy with recombinant growth hormone (somatrem) in adults with growth hormone deficiency, extending the question beyond linear growth to adult metabolic and body-composition physiology (PMID 3481181).

A negative report

Not every study reported a benefit. A Spanish-language report described the null effect of somatrem during typhoid fever, an acute infectious illness state (PMID 1764197). Negative and null findings matter in a physiology library because they show that growth hormone signalling does not produce the same downstream result in every physiological context — acute illness, inflammation, and catabolic states can blunt responsiveness.

Immunogenicity and adverse events: what studies report

The distinguishing safety question for somatrem was antigenicity. Because the molecule differs from native human growth hormone by an added methionine, antibody formation was studied deliberately. An animal immunogenicity model was used during the development of Protropin somatrem specifically to examine immune responses to methionyl human growth hormone (PMID 12434920). Clinically, a 1989 paper reported first-year United Kingdom experience with the antigenicity and efficacy of authentic sequence recombinant human growth hormone (somatropin), framing the comparison between the methionyl and native-sequence products (PMID 2691122). Analytical characterisation of somatropin and its variants supports that distinction at the molecular level (PMID 15659284).

The verified papers above are titles from paediatric endocrinology trials and development reports; they do not provide a complete modern adverse-event profile, and this page does not extrapolate one. Readers who encounter safety claims about somatrem should note that most of the published clinical record predates 1990 and concerns supervised paediatric treatment.

Study map

Why the term still matters

Somatrem is largely a historical name: authentic-sequence somatropin became the standard recombinant growth hormone, and the methionyl variant is no longer a mainstream product. The term persists in three places — older endocrinology literature, regulatory and pharmacopoeial documents about somatropin variants (PMID 15659284), and discussions of protein engineering and immunogenicity, where somatrem is a textbook example of how a single added residue can raise antibody questions (PMID 12434920). Growth hormone and its analogues are prescription medicines in most jurisdictions and are not research-chemical commodities; this page describes published findings only and makes no suggestion about personal use.

Limits of the evidence

• Most somatrem trials cited here are from 1986–1991 and were conducted in supervised paediatric endocrine settings (PMID 3310915).
• Sample sizes, endpoints, and reporting conventions of that era differ from modern trial standards, and the study designs were often open-label experience reports (PMID 3296635).
• Findings in growth-plate-active children do not transfer automatically to adults, where the research question was substitution physiology rather than height (PMID 3481181).
• At least one published report found no effect in an acute infectious illness context (PMID 1764197).

References

• Somatropin and its variants: structural characterization and methods of analysis (Pharmeuropa bio, 2004)
• The use of an animal immunogenicity model in the development of Protropin somatrem (methionyl human growth hormone) (Developments in biologicals, 2002)
• Antigenicity and efficacy of authentic sequence recombinant human growth hormone (somatropin): first-year experience in the United Kingdom (Clinical Endocrinology, 1989)
• United Kingdom multicentre clinical trial of somatrem (Archives of Disease in Childhood, 1987)
• Clinical experience with somatrem in growth hormone deficiency (Acta Paediatrica Scandinavica Supplement, 1986)
• Clinical experience of somatrem: UK preliminary report (Acta Paediatrica Scandinavica Supplement, 1986)
• Clinical experience with somatrem in Japan (Acta Paediatrica Scandinavica Supplement, 1986)
• Treatment of Turner's syndrome with recombinant human growth hormone (somatrem) (Acta Paediatrica Scandinavica Supplement, 1988)
• Results from the first 2 years of a clinical trial with recombinant DNA-derived human growth hormone (somatrem) in Turner's syndrome (Acta Paediatrica Scandinavica Supplement, 1987)
• Substitution therapy with recombinant growth hormone (somatrem) in adults with growth hormone deficiency (Acta Paediatrica Scandinavica Supplement, 1987)
• Knemometry as a predictor of response to somatrem in Turner's syndrome (Acta Paediatrica Scandinavica Supplement, 1987)
• [The null effect of Somatrem during typhoid fever] (Boletin Medico del Hospital Infantil de Mexico, 1991)